# Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

> **NCT03449446** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 395 (actual)

## Conditions studied

- Nonalcoholic Steatohepatitis

## Interventions

- **DRUG:** SEL
- **DRUG:** FIR
- **DRUG:** CILO
- **DRUG:** Placebo to match FIR
- **DRUG:** Placebo to match CILO
- **DRUG:** Placebo to match SEL

## Key facts

- **NCT ID:** NCT03449446
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-21
- **Primary completion:** 2019-10-30
- **Final completion:** 2019-11-19
- **Target enrollment:** 395 (ACTUAL)
- **Last updated:** 2020-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03449446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03449446, "Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03449446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*